Community-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus in a Chinese adult: A case report

Huan Xia1, Jinying Gao1, Ming Xiu2

  • 1Department of Respiratory Medicine.

Medicine
|June 27, 2020
PubMed
Abstract

Insights

Severe community-acquired pneumonia caused by Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus (PVL-MRSA) can rapidly lead to septic shock and death, even in healthy individuals. This rare CA-MRSA pneumonia case highlights the critical need for prompt diagnosis and treatment.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Critical Care Medicine

Background:

  • Methicillin-resistant Staphylococcus aureus (MRSA) is a significant cause of severe community-acquired pneumonia (CAP) with high mortality.
  • Panton-Valentine leukocidin (PVL)-producing MRSA is associated with necrotizing pneumonia and poorer outcomes.
  • Community-acquired MRSA (CA-MRSA) pneumonia is rare, with few cases reported previously.

Observation:

  • A 68-year-old male with no prior medical history presented with symptoms of severe CAP, including high fever, productive cough, and hypodynamia.
  • Despite initial treatment, his condition rapidly deteriorated, leading to dyspnea and hemoptysis.
  • Diagnosis confirmed CA-MRSA pneumonia with septic shock, with MRSA isolates testing positive for PVL genes.

Findings:

  • The patient received mechanical ventilation, fluid resuscitation, and broad-spectrum antibiotics including mezlocillin sodium/sulbactam sodium, linezolid, and oseltamivir.
  • Despite intensive treatment, the patient succumbed to the infection 12 hours after admission.
  • This case underscores the aggressive nature of PVL-positive CA-MRSA pneumonia.

Implications:

  • CA-MRSA should be recognized as a potential pathogen in severe CAP, particularly in previously healthy individuals presenting with rapid deterioration.
  • The presence of PVL in MRSA strains may indicate a higher risk of severe necrotizing pneumonia and septic shock.
  • Prompt recognition and aggressive management are crucial for improving outcomes in patients with PVL-positive CA-MRSA pneumonia.